May 20th, 2021 – Today Visikol joins the CELLINK family through acquisition. The acquisition provides CELLINK the opportunity to enter into the $11.58 billion dollar contract research market, while Visikol is provided with access to the capital and resources necessary for continued growth. Over the the past year Visikol has seen steady growth as well as an increase in the demand for in vitro and imaging projects. To meet the demand of new projects it is necessary to invest in new equipment and technologies which CELLINK provides the opportunity for. From an operations perspective Visikol will continue with current management post-transaction as the company is a subsidiary of CELLINK with the autonomy to operate with current policies & strategy.
“We founded Visikol five years ago with the vision to transform tissues into actionable insights for our customers. Over the years we have developed our offering by combining science with technology, which is spot on what CELLINK is all about. We look forward to being a part of the Group and continue to develop market leading offerings together with our new colleagues.” Michael Johnson, CEO, Visikol.
Looking to the future, we remain steadfast to providing our Clients with leading drug discovery solutions. Be sure to check out the press release and video to learn more about this recent news and reach out to us today if you have any questions or are interested in our services!